Development of Potent and Selective Indomethacin Analogues for the Inhibition of AKR1C3 (Type 5 17β-Hydroxysteroid Dehydrogenase/Prostaglandin F Synthase) in Castrate-Resistant Prostate Cancer

Castrate-resistant prostate cancer (CRPC) is a fatal, metastatic form of prostate cancer. CRPC is characterized by reactivation of the androgen axis due to changes in androgen receptor signaling and/or adaptive intratumoral androgen biosynthesis. AKR1C3 is upregulated in CRPC where it catalyzes the formation of potent androgens. This makes AKR1C3 a target for the treatment of CRPC. AKR1C3 inhibitors should not inhibit AKR1C1/AKR1C2, which inactivate 5α-dihydrotestosterone. Indomethacin, used to inhibit cyclooxygenase, also inhibits AKR1C3 and displays selectivity over AKR1C1/AKR1C2. Parallel synthetic strategies were used to generate libraries of indomethacin analogues, which exhibit reduced cyclooxygenase inhibitory activity but retain AKR1C3 inhibitory potency and selectivity. The lead compounds inhibited AKR1C3 with nanomolar potency, displayed >100-fold selectivity over AKR1C1/AKR1C2, and blocked testosterone formation in LNCaP-AKR1C3 cells. The AKR1C3·NADP+·2′-des-methyl-indomethacin crystal structure was determined, and it revealed a unique inhibitor binding mode. The compounds reported are promising agents for the development of therapeutics for CRPC.

[1]  L. Marnett,et al.  Straightforward protocol for the efficient synthesis of varied N(1)-acylated (aza)indole 2-/3-alkanoic acids and esters: optimization and scale-up. , 2012, Tetrahedron.

[2]  W. Denny,et al.  3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic acids; a New Class of Highly Potent and Selective Inhibitors of the Type 5 17-beta-hydroxysteroid Dehydrogenase AKR1C3 , 2012 .

[3]  S. Turk,et al.  N-Benzoyl anthranilic acid derivatives as selective inhibitors of aldo-keto reductase AKR1C3. , 2012, Bioorganic & medicinal chemistry letters.

[4]  Andrew P. Turnbull,et al.  Crystal Structures of Three Classes of Non-Steroidal Anti-Inflammatory Drugs in Complex with Aldo-Keto Reductase 1C3 , 2012, PloS one.

[5]  Janez Konc,et al.  Selective inhibitors of aldo-keto reductases AKR1C1 and AKR1C3 discovered by virtual screening of a fragment library. , 2012, Journal of medicinal chemistry.

[6]  W. Denny,et al.  3-(3,4-Dihydroisoquinolin-2(1H)-ylsulfonyl)benzoic Acids: highly potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase AKR1C3. , 2012, Journal of medicinal chemistry.

[7]  Barry M. Twenter,et al.  Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer. , 2012, Bioorganic & medicinal chemistry letters.

[8]  T. Penning,et al.  Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride , 2012, The Journal of Steroid Biochemistry and Molecular Biology.

[9]  O. El-Kabbani,et al.  Selective inhibition of human type-5 17β-hydroxysteroid dehydrogenase (AKR1C3) by baccharin, a component of Brazilian propolis. , 2012, Journal of natural products.

[10]  Barry M. Twenter,et al.  Development of potent and selective inhibitors of aldo-keto reductase 1C3 (type 5 17β-hydroxysteroid dehydrogenase) based on N-phenyl-aminobenzoates and their structure-activity relationships. , 2012, Journal of medicinal chemistry.

[11]  Lawrence J. Marnett,et al.  Cyclooxygenase-1-Selective Inhibitors Based on the (E)-2′-Des-methyl-sulindac Sulfide Scaffold , 2012, Journal of medicinal chemistry.

[12]  P. Nelson,et al.  Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. , 2011, Cancer research.

[13]  Yi Jin.  Activities of aldo-keto reductase 1 enzymes on two inhaled corticosteroids: implications for the pharmacological effects of inhaled corticosteroids. , 2011, Chemico-biological interactions.

[14]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[15]  Yi Jin,et al.  Inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3): Overview and structural insights , 2011, The Journal of Steroid Biochemistry and Molecular Biology.

[16]  S. Halder,et al.  Accidental discovery of a ‘longer-range’ vinylogous Pummerer-type lactonization: formation of sulindac sulfide lactone from sulindac , 2011 .

[17]  Barry M. Twenter,et al.  Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3). , 2011, Bioorganic & medicinal chemistry letters.

[18]  K. Knudsen,et al.  Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer , 2010, Trends in Endocrinology & Metabolism.

[19]  D. Dearnaley,et al.  Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Dowsett,et al.  Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  H. Scher,et al.  Starving the Addiction: New Opportunities for Durable Suppression of AR Signaling in Prostate Cancer , 2009, Clinical Cancer Research.

[22]  A. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[23]  T. Penning,et al.  Oxidation of PAH trans-dihydrodiols by human aldo-keto reductase AKR1B10. , 2008, Chemical research in toxicology.

[24]  M. Gleave,et al.  Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. , 2008, Cancer research.

[25]  P. Nelson,et al.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.

[26]  T. Penning,et al.  An indomethacin analogue, N-(4-chlorobenzoyl)-melatonin, is a selective inhibitor of aldo-keto reductase 1C3 (type 2 3alpha-HSD, type 5 17beta-HSD, and prostaglandin F synthase), a potential target for the treatment of hormone dependent and hormone independent malignancies. , 2008, Biochemical pharmacology.

[27]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[28]  Andrew S. Felts,et al.  Desmethyl derivatives of indomethacin and sulindac as probes for cyclooxygenase-dependent biology. , 2007, ACS chemical biology.

[29]  S. Gately,et al.  Novel silicon-containing drugs derived from the indomethacin scaffold: Synthesis, characterization and evaluation of biological activity , 2007 .

[30]  Xiaofei Yu,et al.  Peroxisome proliferator-activated receptor in malignant diseases , 2006 .

[31]  T. Golub,et al.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. , 2006, Cancer research.

[32]  L. Marnett,et al.  Indolyl esters and amides related to indomethacin are selective COX-2 inhibitors. , 2005, Bioorganic & medicinal chemistry.

[33]  Giuseppe Nano,et al.  2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. , 2005, Journal of medicinal chemistry.

[34]  S. Rudnick,et al.  Development of Nonsteroidal Anti-Inflammatory Drug Analogs and Steroid Carboxylates Selective for Human Aldo-Keto Reductase Isoforms: Potential Antineoplastic Agents That Work Independently of Cyclooxygenase Isozymes , 2005, Molecular Pharmacology.

[35]  Andrew S. Felts,et al.  Molecular basis of the time-dependent inhibition of cyclooxygenases by indomethacin. , 2004, Biochemistry.

[36]  Sheng-Xiang Lin,et al.  Crystal structures of the multispecific 17beta-hydroxysteroid dehydrogenase type 5: critical androgen regulation in human peripheral tissues. , 2004, Molecular endocrinology.

[37]  I Judson,et al.  Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer , 2004, British Journal of Cancer.

[38]  C. Bunce,et al.  Crystal Structures of Prostaglandin D2 11-Ketoreductase (AKR1C3) in Complex with the Nonsteroidal Anti-Inflammatory Drugs Flufenamic Acid and Indomethacin , 2004, Cancer Research.

[39]  Taro Yamada,et al.  Crystal structure of human prostaglandin F synthase (AKR1C3). , 2004, Biochemistry.

[40]  T. Penning,et al.  Human cytosolic 3alpha-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3beta-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action. , 2003, The Journal of biological chemistry.

[41]  O. Tamura,et al.  Total synthesis of mappicine ketone (nothapodytine B) by means of sulfur-directed 5-exo-selective aryl radical cyclization onto enamides. , 2003, The Journal of organic chemistry.

[42]  D. Peehl,et al.  Human type 3 3alpha-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells. , 2003, Endocrinology.

[43]  C. Lindsley,et al.  Development of a custom high-throughput preparative liquid chromatography/mass spectrometer platform for the preparative purification and analytical analysis of compound libraries. , 2003, Journal of combinatorial chemistry.

[44]  R. Hayden,et al.  The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs. , 2003, Cancer research.

[45]  J. Jez,et al.  Engineering steroid hormone specificity into aldo-keto reductases. , 2001, Chemico-biological interactions.

[46]  Michael E. Burczynski,et al.  Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1–AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones , 2000 .

[47]  D. Dewitt,et al.  Purification and characterization of the human recombinant histidine-tagged prostaglandin endoperoxide H synthases-1 and -2. , 2000, Archives of biochemistry and biophysics.

[48]  M. Nishizawa,et al.  cDNA cloning, expression and characterization of human prostaglandin F synthase 1 , 1999 .

[49]  H. Shiraishi,et al.  Identification of a principal mRNA species for human 3alpha-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity. , 1998, Journal of biochemistry.

[50]  V. N. Molchanov,et al.  Superconducting Single Crystals of Tl2Ba2CaCu2O8 and YBa2Cu4O8: Crystal Structures in the Vicinity of Tc , 1998 .

[51]  L. Marnett,et al.  Aspirin-like molecules that covalently inactivate cyclooxygenase-2. , 1998, Science.

[52]  T. Penning,et al.  Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7, 8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione. , 1998, Biochemistry.

[53]  J. Falgueyret,et al.  Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX‐2 inhibitor , 1997, British journal of pharmacology.

[54]  R. Copeland,et al.  Expression purification and characterization of recombinant human inducible prostaglandin G/H synthase from baculovirus-infected insect cells. , 1996, Protein expression and purification.

[55]  B. Spiegelman,et al.  15-Deoxy-Δ 12,14-Prostaglandin J 2 is a ligand for the adipocyte determination factor PPARγ , 1995, Cell.

[56]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[57]  J. Pawlowski,et al.  Isolation and partial characterization of a full-length cDNA clone for 3α-hydroxysteroid dehydrogenase: A potential target enzyme for nonsteroidal anti-inflammatory drugs , 1991, Agents and Actions.

[58]  A. W. Douglas,et al.  An unusual Fischer indole synthesis with 4-keto acids: an indole incorporating the terminal hydrazine nitrogen , 1990 .

[59]  T. Penning,et al.  Inhibition of a major NAD(P)-linked oxidoreductase from rat liver cytosol by steroidal and nonsteroidal anti-inflammatory agents and by prostaglandins. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[60]  G. Allen.  Selectivity in the fischer indolization of phenylhydrazones derived from 3-ketocyclohexanecarboxylic acid , 1970 .

[61]  H. Yamamoto.  1-acyl-indoles. II. A new syntheses of 1-(p-chlorobenzoyl)-5-methyoxy-3-indolyacetic acid and its polymorphism. , 1968, Chemical & pharmaceutical bulletin.

[62]  G. Jenster,et al.  Tumor and Stem Cell Biology Cancer Research Evidence of Limited Contributions for Intratumoral Steroidogenesis in Prostate Cancer , 2010 .

[63]  A. Khanna,et al.  an unusual of , 2008 .

[64]  J. Hiratake,et al.  Biological Crystallography , 2022 .

[65]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[66]  Vincent B. Chen,et al.  PHENIX: a comprehensive Python-based system for macromolecular structure solution , 2010, Acta crystallographica. Section D, Biological crystallography.